Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants

The Nuvaxovid™ (NVX-CoV2373) Novavax vaccine is a recombinant spike (S) protein nanoparticle vaccine combined with the Matrix-M adjuvant. On December 20, 2021, the European Commission of the European Union (EU) granted conditional marketing authorization for the Nuvaxovid™ (NVX-CoV2373) Novavax vacc...

Descripción completa

Detalles Bibliográficos
Autor principal: Parums, Dinah V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897963/
https://www.ncbi.nlm.nih.gov/pubmed/35228506
http://dx.doi.org/10.12659/MSM.936523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897963/
https://www.ncbi.nlm.nih.gov/pubmed/35228506
http://dx.doi.org/10.12659/MSM.936523

Ejemplares similares